Analysis of tumour contours and radiotherapy planning of “on-trial” patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Rad...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter E. Fokas
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors E. Fokas1, E. Spezi2, N. Patel3, C. Hurt4, L. Nixon4, K. Chu3, G. Joseph2, J. Staffurth2, R. Abrams5, S. Mukherjee1
  • 1University of Oxford, Oxford, United Kingdom, /
  • 2Velindre NHS Trust, Cardiff, United Kingdom, /
  • 3Churchill Hospital, Oxford, United Kingdom, /
  • 4Wales Cancer Trials Unit, Cardiff University, Cardiff, United Kingdom, /
  • 5Dept. of Radiation Oncology, RUMC, Chicago, Illinois, USA, /

Abstract

The SCALOP trial tested the safety and efficacy of gemcitabine (Gem) versus capecitabine (Cap) based CRT following induction chemotherapy and showed that GemRT was associated with greater toxicity and worse survival1. The evaluation of investigator-delineated volumes and plan assessment from the pre-trial RTQA program using a single benchmark case showed considerable variation in gross tumour volume (GTV) outlining but no major deviations in other aspects of RT planning. The contours and RT plans of on-trial patients have now been centrally reviewed and are presented.